Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma

Table 5 NAT2 Genotype Frequencies in Control Subjects and in Patients with Breast Carcinoma.

NAT2 genotypes	Controls (n = 237)	All Patients (n = 290)	p	OR (95%CI)
	n	n
NAT2*4/4	13	23	NS	1.48(0.7–3.18)
NAT2*4/12A	01	00	NS*	-
NAT2*12A/12A	00	01	NS*	-
NAT2*4/5A	01	07	NS*	-
NAT2*4/5B	41	45	NS	0.88(0.54–1.43)
NAT2*4/6B	32	27	NS	0.66(0.37–1.17)
NAT2*4/7A	05	04	NS*	-
NAT2*12A/5B	21	07	0.001	0.25(0.1–0.65)
NAT2*12A/6B	05	02	NS*	-
NAT2*5A/5B	02	04	NS*	-
NAT2*5A/6B	00	05	0.04*	-
NAT2*5A/7A	00	01	NS*	-
NAT2*5B/5B	35	53	NS	1.29(0.79–2.11)
NAT2*5B/6B	54	68	NS	1.04(0.68–1.59)
NAT2*5B/7A	06	11	NS	1.52(0.51–4.69)
NAT2*6B/6B	15	25	NS	1.40(0.69–2.86)
NAT2*6B/7A	06	07	NS	0.95(0.28–3.24)

The chi-square test was used to determine whether significant differences (p value) were observed when the patient group was compared with the control group. NS: not significant; *: Fisher test was used.

ISSN: 1471-2407